Hepatitis B vaccination;Die impfung gegen hepatitis B

Sozial- und Praventivmedizin

Volumn 43, Issue SUPPL. 1, 1998, Pages

  Desgrandchamps, Daniel ^a,c   Siegrist, Claire Anne ^b  

^a Schweizerische Kommission F I   (Switzerland)

^b Hopital des Enfants Hopitaux universitaires de Geneve   (Switzerland)

^c NONE   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

HEPATITIS B ANTIBODY; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B VACCINE; RECOMBINANT VACCINE;

ANTIBODY TITER; DRUG SAFETY; FEVER; HEPATITIS B; HUMAN; IMMUNOLOGICAL MEMORY; INJECTION PAIN; INTRAMUSCULAR DRUG ADMINISTRATION; REVIEW; SEROCONVERSION; SWITZERLAND; VACCINATION;

ADULT; CHILD; FEMALE; HEPATITIS B; HEPATITIS B ANTIBODIES; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VACCINES; HUMANS; IMMUNIZATION, SECONDARY; INFANT; INFANT, NEWBORN; MALE; PREGNANCY;

EID: 0031727928     PISSN: 03038408     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02042173     Document Type: Review

References (28)

1. Blumberg BS, Alter HJ, Visnich S. A "new" antigen in leukemia sera. JAMA 1965; 91:541-546.
2. Prince AM. An antigen detected in the blood during the incubation period of serum hepatitis. Proc Natl Acad Sci USA 1968; 60:814-821.
3. Valenzuela P, Medina A, Rutter WJ, Ammerer G, Hall BD. Synthesis and assembly of hepatitis B virus surface antigen particles in yeast. Nature 1982; 298:347-350.
4. McAleer WJ, Euynak EB, Maigetter RZ, Wampler DE, Miller WJ, Hilleman MR. Human hepatitis B vaccine from recombinant yeast. Nature 1984; 307:178-180.
5. Adamowicz P, Tron F, Vinas R et al. Hepatitis B vaccine containing the S and Pre-S2 antigens produced in Chinese hamster ovary cells. In: Zuckermann AJ, ed. Viral Hepatitis and Liver Disease. New York: Alan R. Liss, 1988:1087-1090.
6. Szmuness W, Stevens CE, Harley EJ et al. Hepatitis B vaccine: demonstration of efficacy in a controlled clinical trial in a high risk population in the United States. N Engl J Med 1980: 303:833-841.
7. Laplanche A, Courouce A-M, Benhamou E et al. Responses to hepatitis B vaccine. Lancet 1982; 1:222.
8. Zajac BA, West DJ, McAleer WJ, Scolnick EM. Overview of clinical studies with hepatitis B vaccine made by recombinant DNA. J Infect 1986; 13 suppl A:39-45.
9. Centers for Disease Control and Prevention. Recommended childhood immunization schedule - United States, 1995. MMWR 1995; 44 (No RR-5): 5-6.
10. Zuckerman JN, Zuckerman AJ. Acute hepatitis B after vaccination. Lancet 1995; 345:261-262.
11. Stevens CE, Toy PT, Taylor PE, Lee T, Yip H-Y. Prospects for control of hepatitis B virus infection: implication of childhood vaccination and long-term protection. Pediatrics 1992; 90:170-173.
12. Da Villa G, Peluso F, Picciotto L et al. Persistence of anti-HBs in children vaccinated against viral hepatitis B in the first year of life: follow-up at 5 and 10 years. Vaccine 1996; 14:1503-1505.
13. Hadler SC, Francis DP, Maynard JE et al. Long term immunogenicity and efficacy of hepatitis B vaccine in homosexual men. N Engl J Med 1986; 315:209-214.
14. West DJ, Calandra GB. Vaccine induced immunological memory for hepatitis B surface antigen; implications for policy on booster vaccination. Vaccine 1996; 14:734-746.
15. Bundesamt für Gesundheit, Schweizerische Expertengruppe für virale Hepatitis. Hepatitis B-Impfung. Ist eine Auffrischimpfung noch nötig? Bull BAG 1995; (20):12-16 und (37):15-16.
16. Bundesamt für Gesundheit, Schweizerische Expertengruppe für virale Hepatitis. Hepatitis B-Impfung. Ist eine Auffrischimpfung noch nötig? Bull BAG 1995; (20):12-16 und (37):15-16.
17. Stevens CE, Taylor PE, Tong MJ et al. Yeast recombinant hepatitis B vaccine: efficacy with hepatitis B immune globulin in prevention of perinatal hepatitis B virus transmission. JAMA 1987; 257:2612-2616.
18. Resti M, Azzari C, Mannelli F et al. Ten-year follow-up study of neonatal hepatitis B immunization: are booster injections indicated? Vaccine 1997; 15:1338-1340.
19. Chang MH, Chen CJ, Lai MS et al. Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. N Eng J Med 1997; 336:1855-1859.
20. Lemon SM, Thomas DL. Vaccines to prevent viral hepatitis. N Engl J Med 1997; 336:196-204.
21. Bundesamt für Gesundheit, Schweizerische Kommission für Impffragen, Schweizerische Expertengruppe für virale Hepatitis. Empfehlungen zur Hepatitis-B-Impfung. In: Bundesamt für Gesundheit. Infektionskrankheiten-Diagnose und Bekämpfung, Kapitel 1, Suppl. II, Dezember 1997.
22. Centers for Disease Control and Prevention. Update: vaccine side effects, adverse reactions, contraindications and precautions-recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 1996; 45 (No RR-12):7-8.
23. Niu MT, Davis DM, Ellenberg S. Recombinant hepatitis B vaccination of neonates and infants : emerging safety data from the Vaccine Adverse Events Reporting System. Pediatr Infect Dis J 1996; 15:771-776.
24. Gellin BC, Greenberg RN, Hart RH et al. Immunogenicity of two doses of yeast recombinant hepatitis vaccine in healthy older adults. J Infect Dis 1997; 175:1494-1497.
25. Singh M, Li XM, McGee JP et. al. Controlled release microparticles as a single dose hepatitis B vaccine: evaluation of immunogenicity in mice. Vaccine 1997; 15:475-481.
26. Katz SL. Future vaccines and a global perspective. Lancet 1997; 350:1767-1770.
27. Dagan R, Yerushalmi B, Blondheim O et al. Safety and immunogenicity of a new mammalian cell-derived recombinant hepatitis B vaccine containing S, pre-S1 and pre-S2 antigens (Bio-Hep-B) in neonates. 36th Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans 1996.
28. Zuckerman JN, Sabin C, Craig FM, Williams A, Zuckerman AJ. Immune response to a new hepatitis B vaccine in healthcare workers who had not responded to standard vaccine: randomised double blind dose-response study. BMJ 1997; 314:329-333.